ONO Pharmaceutical Co. Ltd.

07/22/2024 | Press release | Distributed by Public on 07/21/2024 23:03

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or[...]

 This material is intended to notify the press release issued on July 19 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.